S 9788

05/01/1996 - "The DT of the tumors increased with DOX over controls (22.5 +/- 8.5/12.7 +/- 3.9 days) and showed a higher value with DOX + S9788 (29.2 +/- 11.4 days). "
05/01/1995 - "HPLC determination of a new multidrug resistance modulator (S9788) extracted from cancer cells in vitro."
02/01/1994 - "Therefore, S9788 should be used as an adjuvant of polychemotherapy against tumors displaying MDR phenotype."
04/01/1993 - "S9788 is therefore a powerful new modifier of the P-gp-mediated multidrug-resistance, which by its pharmacological properties (cellular kinetics and activity), might be used in combination with existing chemotherapy against tumors displaying the MDR phenotype."
11/01/1998 - "In a two step phase I trial we treated 39 patients with refractory cancer with S9788 and bolus doxorubicin. "

11/01/1998 - "Ventricular arrhythmia and torsade de pointe: dose limiting toxicities of the MDR-modulator S9788 in a phase I trial."
01/01/1997 - "Although clinically relevant cardiac toxicities did not occur, the study was terminated as higher doses of S9788 may increase the risk of severe cardiac arrhythmias. "
11/01/1998 - "With the tested infusion schedules, cardiac toxicity, in particular AV-blocks and QT prolongation, leading to ventricular arrhythmia and torsade de pointe, are the dose limiting toxicities of S9788. "

01/01/1997 - "Although clinically relevant cardiac toxicities did not occur, the study was terminated as higher doses of S9788 may increase the risk of severe cardiac arrhythmias. "
11/01/1998 - "With the tested infusion schedules, cardiac toxicity, in particular AV-blocks and QT prolongation, leading to ventricular arrhythmia and torsade de pointe, are the dose limiting toxicities of S9788. "

07/01/1993 - "In a panel of 14 primary cultures of human renal cell carcinomas the reversal of inherent multidrug-resistance by S 9788, a new triazinoaminopiperidine derivative, was analysed. "
07/01/1993 - "Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788."
01/01/1997 - "Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer."
01/01/1997 - "Thirty-eight evaluable patients with advanced colorectal or renal cell cancer were treated with doxorubicin alone (16 patients) followed after disease progression with combination treatment of doxorubicin plus S9788 (12 patients) or upfront with the combination of doxorubicin plus S9788 (22 patients). "

05/01/1996 - "Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma xenograft."
02/01/1995 - "Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line."